Francesca Lavatelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6077286/publications.pdf

Version: 2024-02-01

85 papers	3,507 citations	147801 31 h-index	144013 57 g-index
89 all docs	89 docs citations	89 times ranked	2523 citing authors

#	Article	IF	Citations
1	Proteaseâ€sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. FEBS Journal, 2022, 289, 494-506.	4.7	25
2	Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis. Hemato, 2022, 3, 47-62.	0.6	6
3	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
4	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	7.2	10
5	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. Molecules, 2021, 26, 1913.	3.8	5
6	Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Medicina (Lithuania), 2021, 57, 916.	2.0	2
7	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	10.9	14
8	Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. Journal of Molecular Biology, 2020, 432, 845-860.	4.2	26
9	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. Journal of Biological Chemistry, 2020, 295, 16572-16584.	3.4	32
10	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer Journal, 2020, 10, 90.	6.2	15
11	Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis. Mayo Clinic Proceedings, 2020, 95, 1816-1818.	3.0	3
12	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 168-173.	3.0	6
13	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	1.4	5
14	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 105-106.	3.0	4
15	The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 107-108.	3.0	2
16	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. Analytical Chemistry, 2019, 91, 2894-2900.	6.5	26
17	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1158-H1166.	3.2	17
18	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nature Communications, 2019, 10, 1269.	12.8	113

#	Article	IF	Citations
19	Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. Proteomics, 2018, 18, e1700353.	2.2	6
20	Regulated expression of amyloidogenic immunoglobulin light chains in mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 52-53.	3.0	4
21	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 66-67.	3.0	3
22	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 54-55.	3.0	3
23	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 68-69.	3.0	6
24	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	3.0	9
25	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	3.0	2
26	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 64-65.	3.0	6
27	How do we improve treatments for patients with amyloidosis using proteomics?. Expert Review of Proteomics, 2017, 14, 561-563.	3.0	4
28	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1734-1743.	2.3	33
29	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports, 2017, 7, 15661.	3.3	63
30	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. Scientific Reports, 2017, 7, 16809.	3.3	50
31	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Scientific Reports, 2016, 6, 29096.	3.3	63
32	Advances in proteomic study of cardiac amyloidosis: progress and potential. Expert Review of Proteomics, 2016, 13, 1017-1027.	3.0	4
33	The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 939-45.	2.3	15
34	Systemic amyloidoses and proteomics: The state of the art. EuPA Open Proteomics, 2016, 11, 4-10.	2.5	16
35	A practical approach to the diagnosis of systemic amyloidoses. Blood, 2015, 125, 2239-2244.	1.4	156
36	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.5	60

#	Article	IF	Citations
37	Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. Nutrition, 2015, 31, 1228-1234.	2.4	26
38	The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. Current Clinical Pathology, 2015, , 323-330.	0.0	0
39	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson fromC. elegans. Worm, 2014, 3, e965590.	1.0	9
40	Biochemical markers in early diagnosis and management of systemic amyloidoses. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1517-31.	2.3	22
41	Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. Journal of Parenteral and Enteral Nutrition, 2014, 38, 891-894.	2.6	19
42	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113
43	PP100-SUN: Nutritional Counseling in Systemic Immunoglobulin Light-Chain (AL) Amyloidosis: A Prospective Randomized, Controlled Trial. Clinical Nutrition, 2014, 33, S56-S57.	5.0	1
44	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
45	A Caenorhabditis elegansâ€“based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 2014, 123, 3543-3552.	1.4	122
46	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	3.0	106
47	Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics - Clinical Applications, 2013, 7, 136-143.	1.6	33
48	Shotgun Protein Profile of Human Adipose Tissue and Its Changes in Relation to Systemic Amyloidoses. Journal of Proteome Research, 2013, 12, 5642-5655.	3.7	45
49	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Research in Cardiology, 2013, 108, 378.	5.9	56
50	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. European Heart Journal, 2013, 34, P4239-P4239.	2.2	0
51	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 2013, 98, 433-436.	3.5	65
52	A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli. PLoS ONE, 2013, 8, e76022.	2.5	20
53	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 11-13.	3.0	8
54	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 2012, 119, 1844-1847.	1.4	155

#	Article	IF	Citations
55	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	4.1	95
56	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	1.8	78
57	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Annals of Hematology, 2012, 91, 399-406.	1.8	35
58	Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 177-182.	3.0	50
59	AMICA: an electronic patient record specifically designed for an amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 236-238.	3.0	0
60	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	3.0	4
61	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 64-66.	3.0	17
62	Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 143-145.	0.4	36
63	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 409-419.	2.3	39
64	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 61-63.	3.0	5
65	A workflow management system for the biological samples exchange within the amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 233-235.	3.0	0
66	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	3.0	26
67	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. Blood, 2011, 118, 3977-3977.	1.4	5
68	Pathogenesis of Systemic Amyloidoses. , 2010, , 49-64.		0
69	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. Blood, 2010, 116, 3062-3062.	1.4	0
70	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	3.2	225
71	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8
72	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100

#	Article	IF	Citations
73	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
74	AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity. Clinical Lymphoma and Myeloma, 2009, 9, 80-83.	1.4	45
75	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. Molecular and Cellular Proteomics, 2008, 7, 1570-1583.	3.8	134
76	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	1.4	182
77	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
78	A Proteomic Approach to the Study of Systemic Amyloidoses. , 2007, , 360-362.		1
79	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis. , 2007, , 273-274.		0
80	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al. , 2007, , 390-392.		0
81	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone. , 2007, , 282-282.		0
82	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. American Journal of Clinical Nutrition, 2006, 83, 350-354.	4.7	53
83	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	1.4	266
84	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2006, 108, 5449-5449.	1.4	0
85	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	1.4	207